Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 3
2008 2
2009 2
2016 3
2017 3
2018 3
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
Moore TV, Scurti GM, DeJong M, Wang SY, Dalheim AV, Wagner CR, Hutchens KA, Speiser JJ, Godellas CV, Fountain C, Fleser J, Moudgil T, Thomas M, Murray D, Curti BD, Clark JI, Fox BA, Nishimura MI. Moore TV, et al. Mol Ther Oncolytics. 2021 Jan 26;20:352-363. doi: 10.1016/j.omto.2021.01.014. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2021. PMID: 33614916 Free PMC article.
Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.
Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI. Moore T, et al. Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Cancer Immunol Immunother. 2018. PMID: 29052782 Free PMC article.
Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.
Spear TT, Riley TP, Lyons GE, Callender GG, Roszkowski JJ, Wang Y, Simms PE, Scurti GM, Foley KC, Murray DC, Hellman LM, McMahan RH, Iwashima M, Garrett-Mayer E, Rosen HR, Baker BM, Nishimura MI. Spear TT, et al. J Leukoc Biol. 2016 Sep;100(3):545-57. doi: 10.1189/jlb.2A1215-561R. Epub 2016 Feb 26. J Leukoc Biol. 2016. PMID: 26921345 Free PMC article.
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.
Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, Foley KC, Murray DC, Scurti GM, Li M, Thomas JT, Langerman A, Garrett-Mayer E, Zhang Y, Nishimura MI. Spear TT, et al. Cancer Immunol Immunother. 2016 Mar;65(3):293-304. doi: 10.1007/s00262-016-1800-2. Epub 2016 Feb 3. Cancer Immunol Immunother. 2016. PMID: 26842125 Free PMC article.
16 results